**Table 3.** A summary of outcomes of allo-SCT for relapsed or refractory FL underwent alloSCT

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **n°pts** | **Conditioning regimen** | **TRM** | **EFS/PFS** | **OS** | **REF** |
| Khouri, et al. 2001# | 20 | Flu/Cy - Flu/Cy/Ritux | 10% at 2 year | 84% at 2 year | 84% at 2 year | 79 |
| Robinson et al. 2002 | 52 | Fludarabine-based | 22% | 61% at 1 year | 73% at 1 year | 90 |
| Morris et al. 2004% | 41 | Flu/Mel/Campath-1H | 11% at 3 year | 65% at 3 year | 55% at 3 year | 86 |
| Faulkner et al. 2004& | 28 | BEAM/Campath-1H | 13.3% | 69% at 2 year | 63.1% at 3 year | 84 |
| Corradini et al, 2007\* | 27 | Flu/Cy/Thiotepa | 14% at 3 year\* | 86%at 3 year | 88% at 3 year | 81 |
| Khouri et al, 2008 | 47 | Flu/Cy/Ritux | 15% at 5 year | 85% at 5 year | 83% at 5 year | 80 |
| Hari et al, 2008 | 88 | RIC | 27% at 3 year | 55% at 3 year | 62% at 3 year | 82 |
| Hari et al, 2008 | 120 | MAC | 25% at 3 year | 67% at 3 year | 71% at 3 year | 82 |
| Thomson et al, 2010 | 82 | Flu/Mel/Alemtuzumab | 15% at 4 year | 74% at 4 year | 76% at 4 year | 92 |
| Pinana et al. 2010 | 37 | Flu-Mel | 41% at 4 year | 57% at 4 year | 54% at 4 year | 87 |
| Delgado et al. 2011 | 164 | RIC | 17% at 3 year | 58% at 5 year | 72% at 5 year | 82 |
| Robinson et al. 2013 | 149 | RIC | 22% at 3 year | 57% at 5 year | 67% at 5 year | 89 |
| Evens et al. 2013 | 48 | RIC | 24% at 3 year | 52% at 3 year | 61% at 3 year | 83 |
| Klyuchnikov et al. 2015 | 268 | RIC | 26% at 5 year | 58% at 5 year | 66% at 5 year | 41 |
| Klyuchnikov et al, 2016 | 61 | RIC | 27% at 5 year | 51% at 5 year | 54% at 5 year | 42 |
| Robinson 2016+ | 183 | RIC | 27% at 2 years | 48% at 5 year | 51% at 5 year | 95 |

#Also Small Lymphocytic Lymphoma included

%29/41 of indolent lymphoma group were FL

\*including also other indolent lymphomas

&including also other indolent lymphoma

+All patients relapsed after ASCT